PMCB Overview

Autodesk's Strong Performance: Autodesk Inc reported third-quarter results with adjusted EPS of $2.67 and revenue of $1.85 billion, both exceeding analyst expectations, leading to a 6.1% increase in share price during pre-market trading.

Other Notable Gainers: Mobile-Health Network Solutions surged 45.4%, Inno Holdings gained 29.5%, and KALA Bio increased by 24.1% in pre-market trading, driven by various positive developments and agreements.

Significant Losers: Nutanix Inc saw a 16.8% drop after disappointing financial results and lowered sales guidance, while Biomx Inc and Kaixin Holdings also experienced notable declines of 13.2% and 12.1%, respectively.

Market Overview: The pre-market trading session showed mixed results, with several companies like Urban Outfitters and Petco Health and Wellness reporting better-than-expected earnings, while others faced declines due to poor financial performance.

PharmaCyte Biotech's Investment: PharmaCyte Biotech has increased its investment in TNF Pharmaceuticals by $3 million to support TNF's acquisition of a license from LightSolver, a company recognized for its innovative computing technology that significantly reduces energy consumption and enhances computational speed.

Future Prospects and Strategy: TNF Pharmaceuticals plans to rebrand and focus on applying LightSolver's technology to cryptocurrency mining and blockchain, while PharmaCyte remains financially strong with over $55 million in assets and is exploring further investment opportunities.

Financing Announcement: PharmaCyte Biotech, Inc. has entered into a $7.0 million financing agreement with existing investors, involving the sale of 7,000 shares of Series C convertible preferred stock and warrants for common stock.

Details of Securities: The preferred stock is convertible into 7,000,000 shares of common stock at a price of $1.00 per share, with a 7.0% quarterly cash dividend. The associated warrants also have an exercise price of $1.00 and are valid for five years.

Confidence in Future: Interim CEO Josh Silverman expressed that this financing reflects strong investor confidence in PharmaCyte's future and aims to enhance shareholder value while pursuing strategic alternatives.

Regulatory Compliance: The securities were sold under exemptions from registration requirements, and PharmaCyte plans to file a registration statement with the SEC for the resale of shares issued through this private placement.